Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 522 across all filing types
Latest filing 2024-11-04 Regulatory Filings
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) dated November 4, 2024. It details positive Phase 3 trial results for an experimental drug (Olanzapine LAI) and real-world data for an existing drug (UZEDY®), presented at a medical conference (Psych Congress 2024). It includes quotes from management and links to the full press release from the partner company (Teva). This format—a brief announcement summarizing key operational and clinical updates, often released outside of standard SEC filing cycles—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release announcing clinical/business updates rather than a formal financial report (like 10-K or IR) or a specific regulatory filing like a Director's Dealing or Dividend Notice, it fits best under the general announcement category. Given the focus on clinical data and business updates, and the fact that it is a press release, it is classified as an Earnings Release (ER) as these often accompany or precede formal financial reporting periods, or as a general Regulatory Filing (RNS). Since it is not strictly financial results (like revenue/net income), RNS is a strong candidate, but ER often covers significant operational milestones announced via press release. However, the content is heavily focused on clinical trial data and partnership updates, not quarterly financial performance highlights. Therefore, RNS (Regulatory Filings - general regulatory announcements/fallback) is the most appropriate classification for a non-standard, operational press release.
2024-11-04 French
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information relative au nombre d'actions composant le capital social et au nombre total des droits de vote" (Information relative to the number of shares comprising the share capital and the total number of voting rights). It explicitly provides a table detailing the number of outstanding shares and the total gross and net voting rights as of September 30th, referencing Article 223-16 of the AMF General Regulation. This type of mandatory disclosure, focusing specifically on the calculation basis for voting rights and share capital structure, is a specific regulatory filing. While it relates to capital structure, it is not a general financing announcement (CAP) or a share issue/change announcement (SHA). It is a specific notification about voting rights and capital structure, which fits best under the general regulatory filing category (RNS) or potentially a specific capital/share notification if one were more precise. Given the focus on voting rights calculation based on AMF rules, it is a mandatory regulatory disclosure. Since there isn't a specific code for 'Voting Rights Disclosure', RNS (Regulatory Filings) is the most appropriate fallback for this specific, periodic regulatory update that isn't a full financial report or a director dealing report. The document length is short (3265 chars), but it is the primary content, not an announcement of another document.
2024-10-30 French
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 99% confidence The document is a press release dated October 28, 2024, announcing Medincell's participation schedule in several upcoming investor conferences (Truist, UBS, Jefferies, Evercore ISI) during November and December 2024. This type of announcement, which details management's schedule for meeting with investors and analysts at industry events, is typically classified as Investor Presentation (IP) material or, more broadly, as an announcement related to investor relations activities. Since the document itself is an announcement about future events rather than the presentation slides (IP) or a formal regulatory filing, and it focuses entirely on investor engagement, it aligns best with the general category for investor-focused communications that aren't formal reports or earnings releases. However, given the specific options, this is a direct communication to investors about management availability, which often precedes or accompanies investor presentations. Since there is no specific code for 'Investor Conference Schedule Announcement', and it is not a formal report (10-K, IR), earnings release (ER), or proxy (DEF 14A), the closest fit among the provided options that relates to investor engagement and presentation opportunities is Investor Presentation (IP), although it is an announcement *about* presentations. Given the short length and announcement nature, RPA or RNS could be considered, but the content is highly specific to investor relations activities, making IP a stronger thematic fit if the system interprets 'IP' broadly to cover investor engagement schedules, or RNS as a general regulatory announcement. Given the focus on management meetings at investor conferences, it is a key part of investor relations communication. I will classify it as Investor Presentation (IP) as it directly relates to management's engagement strategy with investors, which is the core function of an IP document, even if this is just the schedule announcement.
2024-10-28 French
Inside Information / Other news releases
Report Publication Announcement Classification · 99% confidence The document is a press release announcing the company's management team's participation schedule in several upcoming investor conferences (Truist Securities BioPharma Symposium, UBS Global Healthcare Conference, Jefferies London Healthcare Conference, and Evercore ISI HealthCONx Conference) during November and December 2024. This type of announcement, which details planned meetings and presentations for investors, is typically classified as Investor Presentation (IP) material or related communication, but given the specific list of definitions, it most closely aligns with communications intended for investors regarding future engagement and strategy presentation opportunities. However, since it is purely an announcement of *participation* in external events rather than the presentation material itself, and it is a general corporate communication, it fits best under the general category for investor-focused announcements that aren't formal financial reports or specific director dealings. Reviewing the definitions, 'Investor Presentation (IP)' is for the detailed presentation itself. This document is an announcement about future investor engagement. It is not a formal regulatory filing (10-K, IR, ER, etc.). It is a corporate communication aimed at investors. Since there isn't a specific 'Investor Conference Schedule Announcement' code, and it is a direct communication to the investment community about management availability, it is often grouped with Investor Relations materials. Given the options, and recognizing this is a proactive communication to investors about management visibility, it is closest to Investor Presentation (IP) or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Since it details management's planned activities to discuss strategy and financials, IP is the most contextually relevant category for investor-facing material, even if it's just the schedule. However, if we strictly follow the definitions, this is an announcement about future events, not the presentation itself. It is a general corporate announcement. Given the short length and the nature of announcing future events, it could be RNS, but since the content is entirely focused on investor relations activities, IP is a strong candidate if we interpret it broadly as 'Investor Relations Material'. Let's re-evaluate: It is a press release detailing management's schedule for investor meetings/presentations. This is standard IR activity. If it were a presentation deck, it would be IP. Since it's just the schedule, it's a general corporate announcement. I will classify it as RNS (Regulatory Filings) as the fallback for general corporate announcements that don't fit the specific financial/governance codes, as it is not a formal report (10-K, IR) nor a specific notice (DIV, DIRS, etc.).
2024-10-28 English
Franchissement de seuil
Major Shareholding Notification Classification · 99% confidence The document is a formal declaration ('Déclaration de franchissement de seuil') dated September 30, 2024, concerning Mirova crossing the 5% threshold of voting rights in MEDINCELL on September 26, 2024. This type of filing, which reports changes in significant share ownership levels crossing regulatory thresholds (like 5%), directly corresponds to the definition of Major Shareholding Notification (MRQ). The reference to 'article L. 233-7 du code de commerce' confirms its regulatory nature regarding shareholding disclosure.
2024-10-01 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release issued by Medincell regarding clinical trial results for a drug (Olanzapine LAI) developed in partnership with Teva. It provides updates on efficacy, safety, and tolerability data presented at a medical congress (ECNP 2024). As this is a general corporate announcement regarding business and clinical developments that does not fit into specific financial reporting categories like 10-K, IR, or ER, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2024-09-23 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.